CN104815192A - 一种治疗高血压的药物组合物及其应用 - Google Patents
一种治疗高血压的药物组合物及其应用 Download PDFInfo
- Publication number
- CN104815192A CN104815192A CN201510218700.2A CN201510218700A CN104815192A CN 104815192 A CN104815192 A CN 104815192A CN 201510218700 A CN201510218700 A CN 201510218700A CN 104815192 A CN104815192 A CN 104815192A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- grams
- vine
- mulberry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 75
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 53
- 240000000249 Morus alba Species 0.000 claims abstract description 45
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 45
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 32
- 244000268590 Euryale ferox Species 0.000 claims abstract description 27
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 25
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 25
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 25
- 241001523681 Dendrobium Species 0.000 claims abstract description 25
- 241000893536 Epimedium Species 0.000 claims abstract description 25
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 25
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 25
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract description 25
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 25
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 25
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 25
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 25
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 25
- 241001522129 Pinellia Species 0.000 claims abstract description 25
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 25
- 235000010674 Prunella vulgaris Nutrition 0.000 claims abstract description 25
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 25
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 25
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 25
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 25
- 241001078983 Tetradium ruticarpum Species 0.000 claims abstract description 25
- 241000157352 Uncaria Species 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims abstract description 25
- 235000018905 epimedium Nutrition 0.000 claims abstract description 25
- 241000722953 Akebia Species 0.000 claims abstract description 24
- 244000280244 Luffa acutangula Species 0.000 claims abstract description 24
- 235000009814 Luffa aegyptiaca Nutrition 0.000 claims abstract description 24
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 24
- 235000004347 Perilla Nutrition 0.000 claims abstract description 24
- 240000007651 Rubus glaucus Species 0.000 claims abstract description 24
- 241000234653 Cyperus Species 0.000 claims abstract description 23
- 241000305491 Gastrodia elata Species 0.000 claims abstract description 23
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 23
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 23
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 23
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 22
- 240000007890 Leonurus cardiaca Species 0.000 claims abstract description 21
- 244000248557 Ophiopogon japonicus Species 0.000 claims abstract description 19
- 240000001972 Gardenia jasminoides Species 0.000 claims abstract description 17
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 12
- 240000005250 Chrysanthemum indicum Species 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- 239000000284 extract Substances 0.000 claims description 25
- 235000013399 edible fruits Nutrition 0.000 claims description 23
- 241000208688 Eucommia Species 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 21
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 239000000080 wetting agent Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 230000000422 nocturnal effect Effects 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000004513 sizing Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 241001521901 Tribulus lanuginosus Species 0.000 claims 8
- 241000219138 Luffa Species 0.000 claims 1
- 235000003956 Luffa Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract description 15
- 244000237330 gutta percha tree Species 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 abstract description 2
- 241000819233 Tribulus <sea snail> Species 0.000 abstract description 2
- 229940047183 tribulus Drugs 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 45
- 230000036772 blood pressure Effects 0.000 description 36
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 210000003734 kidney Anatomy 0.000 description 31
- 239000000047 product Substances 0.000 description 24
- 208000002173 dizziness Diseases 0.000 description 23
- 231100000869 headache Toxicity 0.000 description 22
- 206010019233 Headaches Diseases 0.000 description 21
- 208000002193 Pain Diseases 0.000 description 20
- 241001533104 Tribulus terrestris Species 0.000 description 17
- 230000017531 blood circulation Effects 0.000 description 16
- 230000001737 promoting effect Effects 0.000 description 16
- 206010011224 Cough Diseases 0.000 description 15
- 206010012735 Diarrhoea Diseases 0.000 description 15
- 235000009508 confectionery Nutrition 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 15
- 241000736199 Paeonia Species 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 206010047700 Vomiting Diseases 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 11
- 230000008673 vomiting Effects 0.000 description 11
- 230000003276 anti-hypertensive effect Effects 0.000 description 10
- 230000001603 reducing effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 208000004998 Abdominal Pain Diseases 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 8
- 241000157835 Gardenia Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000036461 convulsion Effects 0.000 description 8
- 230000035487 diastolic blood pressure Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 206010007247 Carbuncle Diseases 0.000 description 7
- 206010033557 Palpitations Diseases 0.000 description 7
- 239000002220 antihypertensive agent Substances 0.000 description 7
- 229940127088 antihypertensive drug Drugs 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 230000004438 eyesight Effects 0.000 description 7
- 208000034783 hypoesthesia Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 208000000059 Dyspnea Diseases 0.000 description 6
- 206010013975 Dyspnoeas Diseases 0.000 description 6
- 206010028813 Nausea Diseases 0.000 description 6
- 230000001914 calming effect Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000002398 materia medica Substances 0.000 description 6
- 230000005906 menstruation Effects 0.000 description 6
- 230000008693 nausea Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000010926 purge Methods 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 241001668545 Pascopyrum Species 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 208000009205 Tinnitus Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 208000013220 shortness of breath Diseases 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 231100000886 tinnitus Toxicity 0.000 description 5
- WUYQEGNOQLRQAQ-CQSZACIVSA-N (+)-pronuciferine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=C3C=21)OC)OC)C13C=CC(=O)C=C1 WUYQEGNOQLRQAQ-CQSZACIVSA-N 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 208000007530 Essential hypertension Diseases 0.000 description 4
- 241000207925 Leonurus Species 0.000 description 4
- 206010059013 Nocturnal emission Diseases 0.000 description 4
- 206010031127 Orthostatic hypotension Diseases 0.000 description 4
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 208000004044 Hypesthesia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000001089 Multiple system atrophy Diseases 0.000 description 3
- 206010028735 Nasal congestion Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 229960002877 dihydralazine Drugs 0.000 description 3
- VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000036513 peripheral conductance Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 206010046901 vaginal discharge Diseases 0.000 description 3
- WUYQEGNOQLRQAQ-UHFFFAOYSA-N (+)-pronuciferine Natural products C1=2C3=C(OC)C(OC)=CC=2CCN(C)C1CC13C=CC(=O)C=C1 WUYQEGNOQLRQAQ-UHFFFAOYSA-N 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 2
- IGWDEVSBEKYORK-UHFFFAOYSA-N isoimperatorin Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)C IGWDEVSBEKYORK-UHFFFAOYSA-N 0.000 description 2
- 201000005630 leukorrhea Diseases 0.000 description 2
- 201000005857 malignant hypertension Diseases 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229930001545 pronuciferine Natural products 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- QQKAHDMMPBQDAC-CQSZACIVSA-N (6ar)-1,2-dimethoxy-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1NCC3 QQKAHDMMPBQDAC-CQSZACIVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- ZPSAEGUNYMEKBP-UHFFFAOYSA-N 5-Isopentenyloxy-psoralen Natural products CC(C)C=COc1c2C=CC(=O)Oc2cc3occc13 ZPSAEGUNYMEKBP-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- BEYIWVKWKJROGZ-UHFFFAOYSA-N Alloimperatorin Natural products O1C(=O)C=CC2=C1C(O)=C1OC=CC1=C2OCC=C(C)C BEYIWVKWKJROGZ-UHFFFAOYSA-N 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017367 Frequent bowel movements Diseases 0.000 description 1
- 208000009693 Gingival Hyperplasia Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010058179 Hypertensive emergency Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000893859 Matelea Species 0.000 description 1
- KGGUASRIGLRPAX-UHFFFAOYSA-N Meranzin hydrate Natural products C1=CC(=O)OC2=C(CC(O)C(C)(C)O)C(OC)=CC=C21 KGGUASRIGLRPAX-UHFFFAOYSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000229722 Perilla <angiosperm> Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 201000003099 Renovascular Hypertension Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 240000001638 Scurrula parasitica Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000055320 Viscum coloratum Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- -1 amipapaverine Chemical compound 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- OLOOJGVNMBJLLR-UHFFFAOYSA-N imperatorin Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OCC=C(C)C OLOOJGVNMBJLLR-UHFFFAOYSA-N 0.000 description 1
- XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 1
- 229960002525 mecamylamine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000023482 precordial pain Diseases 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940068797 tribulus terrestris extract Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗高血压的药物组合物,所述药物组合物的原料药由黄芩、白芷、徐长卿、荷叶、地龙、淫羊藿、麦冬、钩藤、葛根、杜仲、吴茱萸、夏枯草、菊花、天麻、夜交藤、桑寄生、益母草、香附、半夏、木通、芡实、沙棘、丝瓜藤、桑叶、牡丹皮、紫苏、银杏叶、白蒺藜、栀子、覆盆子、石斛、绞股蓝组成。该药物组合物配伍符合中药“君臣佐使”原则,重点突出,全面合理,药效强、药力迅速、药效稳定,具有泻肝定惊,平肝活血等功效。对治疗高血压有良好效果,且具有不易复发、无副作用等特点。
Description
技术领域
本发明属于医药技术领域,涉及一种中药组合物,具体涉及一种治疗高血压的药物组合物及其应用。
背景技术
高血压(hypertensive disease)是一种以动脉血压持续升高为主要表现的慢性疾病,常引起心、脑、肾等重要器官的病变并出现相应的后果。按照世界卫生组织(WHO)建议使用的血压标准是:凡正常成人收缩压应小于或等于140mmHg(18.6kPa),舒张压小于或等于90mmHg(12kPa)。亦即收缩压在141~159mmHg(18.9~21.2kPa)之间,舒张压在91~94mmHg(12.1~12.5kPa)之间,为临界高血压。诊断高血压时,必须多次测量血压,至少有连续两次舒张压的平均值在90mmHg(12.0kPa)或以上才能确诊为高血压。仅一次血压升高者尚不能确诊,但需随访观察。
高血压症状:
头疼:部位多在后脑,并伴有恶心、呕吐等症状。若经常感到头痛,而且很剧烈,同时又恶心作呕,就可能是向恶性高血压转化的信号。
眩晕:女性患者出现较多,可能会在突然蹲下或起立时有所感觉。
耳鸣:双耳耳鸣,持续时间较长。
心悸气短:高血压会导致心肌肥厚、心脏扩大、心肌梗死、心功能不全。这些都是导致心悸气短的症状。
失眠:多为入睡困难、早醒、睡眠不踏实、易做噩梦、易惊醒。这与大脑皮质功能紊乱及自主神经功能失调有关。
肢体麻木:常见手指、脚趾麻木或皮肤如蚁行感,手指不灵活。身体其他部位也可能出现麻木,还可能感觉异常,甚至半身不遂。
高血压的发病机制:
1、习惯因素遗传:大约半数高血压患者有家族史,对季节变化忽略添加应季服装。
2、环境因素:科学研究表明,环境中缺乏负离子也是高血压发病的重要机制。空气负离子经呼吸道入肺,通过膜交换系统进入血液循环,随血液循环到达全身各组织器官,以直接刺激、神经反射以及通过体液方式作用于机体各系统,产生良好的生理效应。当负离子进入血液后,释放出电荷,尽管微乎其微,但对于平衡状态下的血液电荷却很敏感。它会直接影响血液中带电粒子(蛋白质、血细胞)的组成与分布情况,使异常的血液形态与理化特征正常化;并通过促进机体组织的氧化还原过程,特别是通过加强肝、脑、肾等重要组织的氧化过程,激活多种酶系统,对机体的脂肪、蛋白质、碳水化合物、水及电解质代谢起到调整与优化作用。因此,空气中缺乏负离子也是导致高血压产生的一个重要的原因。
3、其他:(1)体重:肥胖者发病率高。(2)避孕药。(3)睡眠呼吸暂停低通气综合征。(4)年龄:发病率着随年龄增长而增高的趋势,40岁以上者发病率高。
高血压是最常见的心血管病,是全球范围内的重大公共卫生问题。2004年的中国居民营养与健康现状调查结果显示,我国18岁及以上居民高血压患病率为18.8%,估计全国患病人数超过1.6亿。与1991年相比,患病率上升31%,患病人数增加约7000多万人。1998年,我国脑血管病居城市居民死亡原因的第二位,在农村居首位。全国每年死亡超过100万,存活的患者约500万~600万,其中75%以上留有不同程度的残疾,给个人、家庭和社会造成了沉重的负担。而脑卒中的主要危险因素是高血压。同时,血压升高还是多种疾病的导火索,会使冠心病、心力衰竭及肾脏疾患等疾病的发病风险增高。由于部分高血压患者并无明显的临床症状,高血压又被称为人类健康的“无形杀手”。因此提高对高血压病的认识,对早期预防、及时治疗有极其重要的意义。
目前,国内外口服降压作用的药物很多,但是口服药属于化学药品,难免会对人体有一些负作用,具体负作用如下:
目前使用降压药对身体的危害:
硝苯啶:本品既可用于慢性高血压的治疗,又可用于高血压急症的紧急治疗。本品有一定的副作用,如面红、头痛、眩晕、乏力、低血压、足部水肿、牙龈增生、皮疹、阳痿等。
肼肽嗪:本品为一种有效的降压药,它可有效地降低原发性高血压或肾血管高血压患者卧位或直立位时的收缩压和舒张压。本品最常见的副作用是引起药物性系统性红斑狼疮,也可引发末梢神经炎、心率增快、心动过速、头痛、低血压等。久服本品尚可出现心悸、气促、倦怠无力、食欲不振、胃肠充气、四肢麻木、失眠、眩晕等不良反应。
双肼苯哒嗪:本品是常用的抗高血压药。它能直接舒张血管平滑肌,使血管扩张、外周阻力降低,血压下降;尚可抑制皮层下血管运动中枢降低血压。但美中不足的是有较多副作用。如头痛头晕、心悸及周围神经系统疾病即感觉异常、麻木等。还可出现恶心、厌食、呕吐、腹泻、鼻塞及体位性低血压等。
敏乐啶:本品主要是通过直接舒张平滑肌而降低血压。其副作用以浮肿常见,这是由于其增加肾小管对钠的重吸收,引起钠及体液的潴留,以及周围血管阻力减低,水分容易渗入组织所致。用药早期易产生头痛,部分病人发生多毛症。
利血平:本品降压作用缓慢、温和而持久,对一、二期高血压而无心、肾血管病变者效果良佳。对三期高血压可加服双肼苯哒嗪,以增强降压效果。其副作用有:鼻粘膜血管扩张而出现鼻塞、消化功能亢进而出现大便次数增多、腹泻、胃酸分泌增加、溃疡病恶心、出血甚至诱发新的溃疡。
美加明:本品能扩张小动脉,使周围血管阻力降低,降压作用强而迅速,血管下降平稳,口服本品0.5—2小时产生降压作用,能维持6—12小时,本品不易产生耐受性。本品的主要副作用有口干、便秘、腹胀、消化不良、视力模糊、尿潴留等。
优降宁:本品适用于中度及重度的原发性高血压和肾性高血压。特别是舒张压较高的病人效果更佳。本品降压作用较慢,一般用药1—2周后才出现降压作用,但作用维持时间较久,每日服药1—2次即可。轻度高血压不宜用本品;中度高血压可单用本品或与利尿剂合用;重度高血压应与其它降压药合用。本品的副作用有体位性低血压、水钠潴留、肝细胞坏死、造血机能障碍等。
胍乙啶:本品具有强大而缓慢的降压作用,口服后24小时显效,2—4天达高峰,维持7—10天。该药副作用有恶心、呕吐、鼻塞、心率减慢以及体位性低血压等。
甲基多巴(中枢降压药):单用本品或与其它降压药合用,对各种类型的高血压都有效。本品不良反应有嗜睡、疲劳、眩晕、头痛、皮疹及体位性低血压等。
综上所述,硝苯啶、肼肽嗪、双肼苯哒嗪等药物,这些药物疗效确切,服用方便,但副作用大、价格昂贵、必须长期服药,而且容易产生抗药性而出现反复发作的缺点,由于传统中医药具有强调整体观念、协调阴阳、标本兼治、毒副作用小等优点,它不仅可以有效控制血压,还可以预防并发症及保护脏器,起到标本兼治的目的。但是,目前临床上缺乏有效的降压中成药。
发明内容
本发明针对现有技术中的不足之处,提供一种治疗高血压的药物组合物及其应用,该药物组合物工艺简单,成本低,无副作用,在治疗高血压疾病方面具有显著疗效。
本发明的上述目的是通过下述技术方案来实现的:
一种治疗高血压的药物组合物,所述药物组合物的原料药由黄芩、白芷、徐长卿、荷叶、地龙、淫羊藿、麦冬、钩藤、葛根、杜仲、吴茱萸、夏枯草、菊花、天麻、夜交藤、桑寄生、益母草、香附、半夏、木通、芡实、沙棘、丝瓜藤、桑叶、牡丹皮、紫苏、银杏叶、白蒺藜、栀子、覆盆子、石斛、绞股蓝组成。
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:夏枯草12-20份,黄芩10-16份,芡实3-8份,白芷5-12份,荷叶12-17份,徐长卿7-12份,益母草4-9份,麦冬15-20份,白蒺藜10-15份,菊花8-12份,天麻2-5份,淫羊藿3-7份,桑寄生11-14份,钩藤9-15份,沙棘3-6份,香附8-13份,木通3-5份,杜仲1-3份,丝瓜藤5-10份,吴茱萸5-10份,桑叶13-16份,地龙3-10份,牡丹皮8-13份,银杏叶3-5份,半夏1-3份,葛根5-10份,紫苏3-6份,夜交藤8-13份,栀子3-5份,覆盆子11-15份,石斛5-10份,绞股蓝4-8份。
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:夏枯草12份,黄芩16份,芡实3份,白芷12份,荷叶12份,徐长卿10份,益母草9份,麦冬15份,白蒺藜15份,菊花8份,天麻5份,淫羊藿3份,桑寄生14份,钩藤9份,沙棘6份,香附8份,木通5份,杜仲1份,丝瓜藤10份,吴茱萸5份,桑叶16份,地龙10份,牡丹皮8份,银杏叶5份,半夏1份,葛根10份,紫苏6份,夜交藤8份,栀子3份,覆盆子15份,石斛5份,绞股蓝4份。
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:夏枯草20份,黄芩10份,芡实8份,白芷5份,荷叶17份,徐长卿12份,益母草4份,麦冬20份,白蒺藜10份,菊花12份,天麻2份,淫羊藿7份,桑寄生11份,钩藤15份,沙棘3份,香附13份,木通3份,杜仲3份,丝瓜藤5份,吴茱萸10份,桑叶13份,地龙3份,牡丹皮13份,银杏叶3份,半夏3份,葛根5份,紫苏4份,夜交藤10份,栀子4份,覆盆子13份,石斛6份,绞股蓝5份。
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:夏枯草13份,黄芩11份,芡实4份,白芷6份,荷叶13份,徐长卿7份,益母草5份,麦冬18份,白蒺藜11份,菊花9份,天麻4份,淫羊藿6份,桑寄生12份,钩藤13份,沙棘4份,香附9份,木通4份,杜仲2份,丝瓜藤6份,吴茱萸6份,桑叶14份,地龙5份,牡丹皮10份,银杏叶4份,半夏2份,葛根6份,紫苏5份,夜交藤12份,栀子3份,覆盆子12份,石斛9份,绞股蓝6份。
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:夏枯草17份,黄芩15份,芡实7份,白芷11份,荷叶16份,徐长卿8份,益母草8份,麦冬16份,白蒺藜14份,菊花11份,天麻3份,淫羊藿5份,桑寄生13份,钩藤14份,沙棘5份,香附12份,木通3份,杜仲1份,丝瓜藤10份,吴茱萸9份,桑叶13份,地龙7份,牡丹皮11份,银杏叶3份,半夏1份,葛根10份,紫苏4份,夜交藤11份,栀子4份,覆盆子14份,石斛8份,绞股蓝7份。
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:夏枯草15份,黄芩12份,芡实5份,白芷9份,荷叶15份,徐长卿9份,益母草7份,麦冬19份,白蒺藜13份,菊花10份,天麻4份,淫羊藿4份,桑寄生11份,钩藤11份,沙棘5份,香附10份,木通5份,杜仲3份,丝瓜藤8份,吴茱萸8份,桑叶14份,地龙9份,牡丹皮12份,银杏叶5份,半夏3份,葛根8份,紫苏6份,夜交藤9份,栀子5份,覆盆子12份,石斛7份,绞股蓝7份。
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:夏枯草19份,黄芩14份,芡实6份,白芷7份,荷叶14份,徐长卿9份,益母草6份,麦冬17份,白蒺藜13份,菊花10份,天麻4份,淫羊藿4份,桑寄生11份,钩藤11份,沙棘5份,香附10份,木通5份,杜仲3份,丝瓜藤8份,吴茱萸8份,桑叶14份,地龙4份,牡丹皮9份,银杏叶5份,半夏3份,葛根8份,紫苏3份,夜交藤8份,栀子5份,覆盆子15份,石斛7份,绞股蓝8份。
在一种优选实施方式中,所述药物组合物按照下列方法进行制备:
(1)取权利要求3-8任一所述药物组合物中重量组分的各药材,加入8-12倍量的乙醇中浸泡1.5-2.5小时,加热提取2次,每次1.5-2小时,去上清液,合并提取液,120目滤过,再经截流分子量为8000-12000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.3-1.4的浸膏,加热浓缩至膏状,静置备用;
(2)将乙醇提取过的药渣放入10-12倍量水中,然后放入提取罐加热煮沸1.5-2小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;
(3)将步骤(2)中2次滤液合在一起,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2-3h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状;
(4)将步骤(1)浓缩得到的膏状物与步骤(3)得到的糊状物减压回收乙醇并浓缩至药液浓度为0.65-0.7g生药/mL,抽滤后,滤液的相对密度约为20℃时1.1-1.2;在3000r/min的转速下离心;在60℃-80℃喷雾干燥,得干浸膏;
(5)将步骤(4)制得的干浸膏粉碎,加入适量蔗糖、糊精混合,以乙醇为润湿剂,制粒,干燥,整粒,可制得颗粒剂;或者将步骤(4)制得的干浸膏干燥,粉碎,制成散剂;或者将步骤(4)制得的干浸膏粉碎,加入适量微粉硅胶、α-半乳糖混合,以乙醇为润湿剂,制粒,干燥,整粒,装胶囊,制得胶囊剂;或者将步骤(4)制得的干浸膏粉碎,加入适量蔗糖、糊精混合,以乙醇为润湿剂,制粒,干燥,整粒,压片,制得片剂;或者向上述步骤(4)得到的离心后的浓缩液中加入适量蔗糖、香精混合,灭菌,灌装,制得药液剂。
本发明还涉及一种所述药物组合物在治疗高血压药物中的应用。
本发明所提供的治疗高血压的药物组合物,其以常见的中草药为原料,充分发挥各组分的药性:
黄芩:基原:本品为唇形科植物黄芩的干燥根。性状:本品呈圆锥形。表面棕黄色或深黄色,有稀疏的疣状细根痕。上部较粗糙,有扭曲的纵皱或不规则的网纹,下部有顺纹和细皱。性味:苦,寒。归经:归肺、胆、脾、大肠、小肠经。功效:清热燥湿,泻人解毒,止血,安胎。主治:用于湿温、暑温胸闷呕恶,湿热痞满,泻痢,黄疸,肺热咳嗽,高热烦渴,血热吐衄,痈肿疮毒,胎动不安。
白芷:基原:为伞形科植物兴安白芷、川白芷、杭白芷或云南牛防风的根。化学成份:含异欧前胡素、欧前胡素、佛手柑内酯、珊瑚菜素、氧化前胡素等。性味:辛,温。归经:入肺、髀、胃经。功能主治:祛风,燥湿,消肿,止痛。治头痛,眉棱骨痛,齿痛,鼻渊,寒湿腹痛,肠风痔漏,赤白带下,痈疽疮疡,皮肤燥痒,疥癣。
徐长卿:基原:为萝藦科植物徐长卿的根及根茎或带根全草。化学成份:全草含牡丹酚约1%。又找出有与肉珊瑚甙元、去酰牛皮泊甙元、茸毛牛奶藤甙元和去酰萝藦甙元极为相似的物质以及醋酸、桂皮酸等。根含黄酮甙、糖类、氨基酸、牡丹酚。药理作用:小鼠腹腔注射徐长卿提取液,能显着减少自发活动,但并不延长巴比妥类的睡眠时间,也有镇痛作用。性味:辛,温。功能主治:镇痛,止咳,利水消肿,活血解毒。治胃痛,牙痛,风湿疼痛,经期腹痛,慢性气管炎,腹水,水肿,痢疾,肠炎,跌打损伤,湿疹,荨麻疹,毒蛇咬伤。
荷叶:基原:本品为睡莲科植物莲的干燥叶。化学成份:叶含莲碱、荷叶碱、原荷叶碱、亚美罂粟碱、前荷叶碱、N-去甲基荷叶碱、D-N-甲基乌药碱、番荔枝碱、鹅掌楸碱、槲皮素、异槲皮甙、莲甙、酒石酸、柠檬酸、苹果酸、葡萄糖酸、草酸、琥珀酸、鞣质。还含抗有丝分裂作用的碱性成分。性味:苦,平。归经:归肝、脾、胃经。功效:清热解暑,升发清阳,凉血止血。主治:用于多种出血症及产后血晕。
地龙:味咸性寒,入肝、脾、膀胱经,具有息风止痉、通络等功效。善治中风后气虚血滞、筋脉失养、经络不利诸症及风湿日久、瘀血痹阻经脉、肢节或周身。地龙善通行经络,药理研究证明:地龙煎剂有抗血栓作用,溶栓成分是蛋白酶,能直接水解纤维蛋白,并具有纤溶酶原的激活作用。通过抑制血小板聚集、抗凝血、降低血粘度,从而阻止血栓形成,促进血栓溶解。
淫羊藿,味辛、甘,性温,归肝经、肾经。能补肾阳,强筋骨,祛风湿。用于阳痿遗精,筋骨痿软,风湿痹痛,麻木拘挛;更年期高血压。
麦冬:甘,微苦,微寒。归心、肺、胃经。养阴生津,润肺清心。用于肺燥干咳,虚痨咳嗽,津伤口渴,心烦失眠,内热消渴,肠燥便秘,咽白喉。
钩藤,味甘,性凉。入肝、心经。能清热平肝,熄风定惊。主治小儿惊痫瘈疭,大人血压偏高,头晕、目眩,妇人子痫。其药理作用具有镇静作用和降压作用。
葛根,味甘、辛,性凉。入脾、胃经。具有升阳解肌,透疹止泻,除烦止温的功效。用于伤寒、温热头痛项强,烦热消渴,泄泻,痢疾,癍疹不透,高血压,心绞痛,耳聋。临床上用来治疗高血压病颈项强痛、冠心病心绞痛,而且还具有降血糖作用。
杜仲:补肝肾,强筋骨,安胎。治腰脊酸疼,具有清除体内垃圾,加强人体细胞物质代谢,防止肌肉骨骼老化,平衡人体血压,分解体内胆固醇,降低体内脂肪,恢复血管弹性,利尿清热,广谱抗菌,兴奋中枢神经,提高白血球数量,增强人体免疫力等显著功效。
吴茱萸,辛、苦,热;有小毒。归肝、脾、胃、肾经。散寒止痛,降逆止呕,助阳止泻。用于厥阴头痛,寒疝腹痛,寒湿脚气,痛经,经行腹痛,脘腹胀痛,呕吐吞酸,五更泄泻,外治口疮;高血压。
夏枯草:味苦;辛;性寒。归肝;胆经。清肝明目;散结解毒。主治目翳羞明;目珠疼痛;头痛眩晕;耳鸣;瘰疬;瘿瘤;乳痈;痄腮;痈疖肿毒;急慢性肝炎;高血压病。《滇南本草》载:“祛肝风,行经络。治口眼歪斜,行肝气,开肝郁,止筋骨疼痛,目珠痛,散瘰疬,周身结核。”现代医学研究证实,夏枯草具有显著的降压和抗菌作用。
菊花:甘、苦,微寒。疏风,清热,明目,解毒。治头痛,眩晕,目赤,心胸烦热,疔疮,肿毒。
天麻:性,平。味,甘。主入肝经。本品息风止痉,平抑肝阳,祛风通络。为治眩晕、头痛之要药;又于肢体麻木、手足不遂、风湿痹痛,筋骨拘挛之佳品。
夜交藤:甘微苦,平。入心、肝经。具有养心,安神,通络,祛风等功效。治失眠,劳伤,多汗,血虚身痛,痈疽,瘰疬,风疮疥癣。
桑寄生:为桑寄生科常绿小灌木植物桑寄生Loranthusparasiticus(L.)Merr.或槲寄生Viscumcoloratum(Komar.)Nakai的带叶茎枝。性味苦、甘,平。归肝、肾经。功效:祛风湿,益肝肾,强筋骨。《日华子本草》:助筋骨,益血脉。
益母草:味辛甘,气微温,无毒。入心、肝、膀胱经。活血,祛瘀,调经,消水。治月经不调,胎漏难产,胞衣不下,产后血晕,瘀血腹痛,崩中漏下,尿血,泻血,痈肿疮疡。
香附,辛、微苦、微甘,平。归肝、脾、三焦经。功能主治:行气解郁,调经止痛。用于肝郁气滞,胸、胁、脘腹胀痛,消化不良,胸脘痞闷,寒疝腹痛,乳房胀痛,月经不调,经闭痛经。
半夏:燥湿化痰,降逆止呕,消痞散结。用于痰多咳喘,痰饮眩悸,风痰眩晕,痰厥头痛,呕吐反胃,胸脘痞闷,梅核气;生用外治痈肿痰核。
木通:用于热淋涩痛,水肿等方面,能利水消肿,下利湿热,使湿热之邪下行从小便排出。在体外对革兰阳性菌及革兰阴性杆菌如痢疾杆菌、伤寒杆菌均有抑制作用。对堇色毛癣菌也有不同程度的抑菌作用。
芡实:味甘、涩,性平。归脾、肾经。功能主治:益肾固精,补脾止泻,祛湿止带。用于梦遗滑精,遗尿尿频,脾虚久泻,白浊,带下。《本经》:主湿痹腰脊膝痛,补中除暴疾,益精气,强志,令耳目聪明。《日华子本草》:开胃助气。《纲目》:止渴益肾。治小便不禁,遗精,白浊,带下。《本草从新》:补脾固肾,助气涩精。治梦遗滑精,解暑热酒毒,疗带浊泄泻,小便不禁。《本草新编》云:“芡实,佐使者也,其功全在补肾祛湿……芡实补中去湿,性又不燥,故能去邪水而补真水,与诸补阴药同用,尤能助之以添精,不虑多投而增湿也”。
沙棘,酸、涩,温。功能主治:止咳祛痰,消食化滞,活血散瘀。用于咳嗽痰多,消化不良,食积腹痛,瘀血经闭,跌扑瘀肿。
丝瓜藤,甘,平。功能主治:通经活络,止咳化痰。腰痛,咳嗽,鼻炎,支气管炎。
桑叶,含有黄酮类、生物碱、植物甾醇、桑叶多糖等成分,具有显著的降血糖和抑制血脂升高的作用。
牡丹皮,苦、辛,微寒。归心、肝、肾经。清热凉血,活血化瘀。用于温毒发斑,吐血衄血,夜热早凉,无汗骨蒸,经闭痛经,痈肿疮毒,跌扑伤痛。
紫苏,辛,温。功能主治:散寒解表,理气宽中。用于风寒感冒,头痛,咳嗽,胸腹胀满。
银杏叶:功能主治:平喘、活血化瘀、止痛,用于肺虚咳喘、冠心病、心绞痛、高血脂。
白蒺藜为蒺藜科一年生或多年生草本植物蒺藜Tribulus ter—restris L.的成熟果实。全国大部分地区均产,但以长江以北较多。其味苦、性辛,平,入肝经。具有平肝解郁,祛风明目。用于肝阳眩晕头痛,肝郁胁痛,风热头痛,目赤肿痛,皮肤瘙痒等症。现代药学研究证实,其含挥发油、皂甙,脂肪油、硝酸盐类、树脂、黄酮类化合物及微量生物碱等。白蒺藜提取物,有自然提升睾酮,增长力量,提高整体竞技状态,无毒副作用。
栀子其性寒、味苦,功能与主治:泻火除烦,清热利湿,凉血解毒,《神农本草经》:“主治五内邪气,白癞,赤癞,疮疡......。”
覆盆子,甘、酸,温。归肾、膀胱经。功能主治:益肾,固精,缩尿。用于肾虚遗尿,小便频数,阳痿早泄,遗精滑精。
石斛:性微寒,味甘,入胃、肾经,具有益胃生津,滋阴清热,润肺益肾的功效,用于热伤津液,低热烦渴,舌红少苔;胃阴不足,口渴咽干,呕逆少食,胃脘隐痛,舌光少苔;肾阴不足,视物昏花等证。
绞股蓝:味甘、苦,性微寒;归肺经、脾经、肾经。能益气,安神,降血压,清热解毒,止咳祛痰。少数患者服药后,出现恶心呕吐、腹胀腹泻(或便秘)、头晕、眼花、耳鸣等症状。服绞股蓝后,肠胃蠕动加快,食欲增加耐饥渴的时间长,既治便秘又治便溏。对大脑皮层兴奋和抑制的反应能保持适当的平衡,对中枢神经有双向调节作用。具有优良的镇痛、安眠、抗紧张的功效。在降低心肌壁紧张、缓和脑血管及外周血管阻力的基础上,能增强心脑活力,加大冠状动脉流量,缓和动脉硬化,促使整体循环更加旺盛而流畅。实验证明,不忌食肥腻而服绞股蓝组,与忌肉不服绞股蓝组,定期检查比较,体内胆固与中性脂肪含量相近。由此可见绞股蓝对人体内脂肪有良性转化调节作用。服绞股蓝与不服的老鼠比较,其游泳时间约长31-57%,而体力恢复也快得多,人服绞股蓝后,体力精力更加充沛,不易疲劳,即使疲倦了也易于恢复,从而工作效率大增。人体某部分机能虚弱,会对某些物质产生过敏,而形成支气管喘息、皮肤丘疹、关节疼痛等症,绞股蓝对这些病效果颇佳。
中医理论认为,高血压病属中医“头痛”“眩晕”“肝阳”“肝风”等范畴。《内经》“髓海不足,脑转耳鸣”“诸风掉眩,皆属于肝”等论述,”当人步入中老年时,脏腑功能衰退,尤其是肾精不足,肝失柔顺,脾失健运,心失所主。其基本病机是阴阳失衡,与肝、肾的阴阳盛衰关系密切,多为本虚标实,实为肝气郁结,肝风、肝阳上扰;虚为肾阴亏损,肝火失于滋养,致肝阳偏亢,病久则阴伤气损,导致气阴两虚和阴阳两虚。一般认为,病位在肝,根源在肾。阴虚阳亢的体质是本病的基本病理,本虚标实、虚实夹杂为其主要病机特点。因此,在本发明的药物组合物中,夜交藤养心,安神,通络,祛风,葛根升阳解肌,透疹止泻,除烦止温,钩藤清热平肝,熄风定惊,杜仲补肝肾,强筋骨,天麻息风止痉,平抑肝阳,祛风通络,地龙息风止痉、通络,白芷祛风,燥湿,消肿,止痛,诸药为君药,共同作用,泻肝定惊,平肝活血,祛风通络。桑寄生祛风湿,益肝肾,强筋骨,淫羊藿补肾阳,强筋骨,祛风湿,麦冬养阴生津,润肺清心,吴茱萸散寒止痛,降逆止呕,助阳止泻,芡实益肾固精,补脾止泻,丝瓜藤通经活络,止咳化痰,覆盆子益肾,固精,石斛益胃生津,滋阴清热,润肺益肾,主要能够进一步起到泻肝养肝的作用,故为臣药。夏枯草清肝明目、散结解毒,绞股蓝益气,安神,降血压,清热解毒,黄芩清热燥湿,泻人解毒,栀子泻火除烦,清热利湿,凉血解毒,徐长卿、木通利水消肿,活血解毒,益母草活血,祛瘀,调经,消水,香附行气解郁,调经止痛,半夏燥湿化痰,降逆止呕,消痞散结,牡丹皮、银杏叶清热凉血,活血化瘀,白蒺藜平肝解郁,祛风明目,诸药合用,能够协助君、臣药以加强治疗作用,故为佐药。荷叶清热解暑,升发清阳,凉血止血,菊花疏风,清热,明目,解毒,沙棘止咳祛痰,消食化滞,活血散瘀,紫苏散寒解表,理气宽中,桑叶具有显著的降血糖和抑制血脂升高的作用,为使药。
本发明的治疗高血压的药物组合物配伍符合中药“君臣佐使”原则,重点突出,全面合理,药效强、药力迅速、药效稳定,具有泻肝定惊,平肝活血等功效。对治疗高血压有良好效果,且具有不易复发、无副作用等特点。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合实施例对本发明的技术方案进行清楚、完整地描述。显然,所描述的实施例是本发明的一部分,而不是全部的实施例。基于所描述的本发明的实施例,本领域普通技术人员在无需创造性劳动的前提下所获得的所有其他实施例,都属于本发明保护的范围。除非另有说明,本发明中的乙醇量的百分数是体积百分数,v/v表示溶液的体积比。
实施例1:
本发明的一种治疗高血压的药物组合物,取下列中药原料药:夏枯草12克,黄芩16克,芡实3克,白芷12克,荷叶12克,徐长卿10克,益母草9克,麦冬15克,白蒺藜15克,菊花8克,天麻5克,淫羊藿3克,桑寄生14克,钩藤9克,沙棘6克,香附8克,木通5克,杜仲1克,丝瓜藤10克,吴茱萸5克,桑叶16克,地龙10克,牡丹皮8克,银杏叶5克,半夏1克,葛根10克,紫苏6克,夜交藤8克,栀子3克,覆盆子15克,石斛5克,绞股蓝4克。
实施例2:
本发明的一种治疗高血压的药物组合物,取下列中药原料药:夏枯草20克,黄芩10克,芡实8克,白芷5克,荷叶17克,徐长卿12克,益母草4克,麦冬20克,白蒺藜10克,菊花12克,天麻2克,淫羊藿7克,桑寄生11克,钩藤15克,沙棘3克,香附13克,木通3克,杜仲3克,丝瓜藤5克,吴茱萸10克,桑叶13克,地龙3克,牡丹皮13克,银杏叶3克,半夏3克,葛根5克,紫苏4克,夜交藤10克,栀子4克,覆盆子13克,石斛6克,绞股蓝5克。
实施例3:
本发明的一种治疗高血压的药物组合物,取下列中药原料药:夏枯草13克,黄芩11克,芡实4克,白芷6克,荷叶13克,徐长卿7克,益母草5克,麦冬18克,白蒺藜11克,菊花9克,天麻4克,淫羊藿6克,桑寄生12克,钩藤13克,沙棘4克,香附9克,木通4克,杜仲2克,丝瓜藤6克,吴茱萸6克,桑叶14克,地龙5克,牡丹皮10克,银杏叶4克,半夏2克,葛根6克,紫苏5克,夜交藤12克,栀子3克,覆盆子12克,石斛9克,绞股蓝6克。
实施例4:
本发明的一种治疗高血压的药物组合物,取下列中药原料药:夏枯草17克,黄芩15克,芡实7克,白芷11克,荷叶16克,徐长卿8克,益母草8克,麦冬16克,白蒺藜14克,菊花11克,天麻3克,淫羊藿5克,桑寄生13克,钩藤14克,沙棘5克,香附12克,木通3克,杜仲1克,丝瓜藤10克,吴茱萸9克,桑叶13克,地龙7克,牡丹皮11克,银杏叶3克,半夏1克,葛根10克,紫苏4克,夜交藤11克,栀子4克,覆盆子14克,石斛8克,绞股蓝7克。
实施例5:
本发明的一种治疗高血压的药物组合物,取下列中药原料药:夏枯草15克,黄芩12克,芡实5克,白芷9克,荷叶15克,徐长卿9克,益母草7克,麦冬19克,白蒺藜13克,菊花10克,天麻4克,淫羊藿4克,桑寄生11克,钩藤11克,沙棘5克,香附10克,木通5克,杜仲3克,丝瓜藤8克,吴茱萸8克,桑叶14克,地龙9克,牡丹皮12克,银杏叶5克,半夏3克,葛根8克,紫苏6克,夜交藤9克,栀子5克,覆盆子12克,石斛7克,绞股蓝7克。
实施例6:
本发明的一种治疗高血压的药物组合物,取下列中药原料药:夏枯草19克,黄芩14克,芡实6克,白芷7克,荷叶14克,徐长卿9克,益母草6克,麦冬17克,白蒺藜13克,菊花10克,天麻4克,淫羊藿4克,桑寄生11克,钩藤11克,沙棘5克,香附10克,木通5克,杜仲3克,丝瓜藤8克,吴茱萸8克,桑叶14克,地龙4克,牡丹皮9克,银杏叶5克,半夏3克,葛根8克,紫苏3克,夜交藤8克,栀子5克,覆盆子15克,石斛7克,绞股蓝8克。
其中,实施例1-6的所述中药组合物的制备方法为:
(1)取实施例1-6任一所述中药组合物中重量组分的各药材,加入8-12倍量的乙醇中浸泡1.5-2.5小时,加热提取2次,每次1.5-2小时,去上清液,合并提取液,120目滤过,再经截流分子量为8000-12000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.3-1.4的浸膏,加热浓缩至膏状,静置备用;
(2)将乙醇提取过的药渣放入10-12倍量水中,然后放入提取罐加热煮沸1.5-2小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;
(3)将步骤(2)中2次滤液合在一起,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2-3h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状;
(4)将步骤(1)浓缩得到的膏状物与步骤(3)得到的糊状物减压回收乙醇并浓缩至药液浓度为0.65-0.7g生药/mL,抽滤后,滤液的相对密度约为20℃时1.1-1.2;在3000r/min的转速下离心;在60℃-80℃喷雾干燥,得干浸膏;
(5)将步骤(4)制得的干浸膏粉碎,加入适量蔗糖、糊精混合,以乙醇为润湿剂,制粒,干燥,整粒,可制得颗粒剂;或者将步骤(4)制得的干浸膏干燥,粉碎,制成散剂;或者将步骤(4)制得的干浸膏粉碎,加入适量微粉硅胶、α-半乳糖混合,以乙醇为润湿剂,制粒,干燥,整粒,装胶囊,制得胶囊剂;或者将步骤(4)制得的干浸膏粉碎,加入适量蔗糖、糊精混合,以乙醇为润湿剂,制粒,干燥,整粒,压片,制得片剂;或者向上述步骤(4)得到的离心后的浓缩液中加入适量蔗糖、香精混合,灭菌,灌装,制得药液剂。
急性毒性试验
方法一:
试验材料:昆明种小鼠60只,体重22-25g。药物:本发明实施例4制得的药液剂,含0.037mg/ml。
方法:
LD50计算:采用改良寇氏法,将小鼠随机分成4组,每组15只,将本发明实施例3制得的药液剂加蒸馏水溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,观察动物死亡情况。
试验结果:在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时(18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,给药后观察14天,小鼠无一死亡,主要脏器未见异常,亦未见其它明显异常,第14天处死并剖检部分小鼠,肉眼观察主要脏器未见异常。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。
六个月长期毒性试验:给药期间每周称体重一次,每日称食量,无死亡或濒死动物,结果小鼠毛色光洁,行为活动、腺体分泌、呼吸、粪便性状均正常。病理检查提示,对各种脏器无明显药物所致病理改变。
临床论证:
为了验证本发明药物组合物的效果,2012年10月-2014年5月,门诊处随机抽取高血压患者300例,采用随机数字表法分为两组,治疗组150例,男72例,女78例,年龄25-76岁,平均(44.5±4.4)岁,病程5-21年,平均10.7年;对照组150例,男76例,女74例,年龄24-71岁,平均(45.9±5.1)岁,病程7-24年,平均11.7年。两组在性别、年龄、病程等方面经统计学处理,差异均无统计算意义(P>0.05)。
诊断标准:
采用《中国高血压防治指南(2010年)》中高血压病的诊断标准,即3次不同时间测量血压,舒张压(DBP)90mmHg或收缩压(SBP)140mmHg;中医辨证属《中药新药临床研究指导原则(试行)》的证型;均为原发性高血压病患者。
治疗
对照组服用珍菊降压片(华佗国药股份有限公司),每次3片,每日3次。
治疗组使用实施例3之片剂来进行治疗,每次两片,每日2-3次。治疗组和对照组均以三周为一个疗程,连续服用3个疗程。
疗效判定标准
治愈:治疗后1-3级高血压患者和单纯收缩期高血压患者,收缩压和舒张压均处于正常范围,维持三个月无反弹;
显效:治疗后2级和3级高血压患者降到1级,维持三个月无反弹;
好转:3级高血压患者降到2级,维持三个月无反弹;
无效:治疗后血压值无变化或加重。
结果:
两组病例治疗后的疗效对照结果如下表:
两组患者临床疗效比较(例%)
组别 | 例数 | 治愈 | 显效 | 有效 | 无效 | 总有效 |
治疗组 | 150 | 77(51.3%) | 34(22.7%) | 35(23.3%) | 4(2.7%) | 137(97.3%) |
对照组 | 150 | 23(15.3%) | 27(18%) | 33(22%) | 67(31.3%) | 83(55.3%) |
两组患者临床疗效比较:治疗组总有效率为97.3%,对照组为55.3%,两组比较差异有统计学意义(P<0.05)。治疗组优于对照组。治疗组无不良副作用,对照组副作用病例7例。可见,本发明优选实施方式制得的药物能够安全有效治疗高血压,有效率显著高于对照组。
下面是发明人日常门诊所接触的典型病例:
病例1:
赵某,男,64岁,青岛市南区人。患者2013年3月就诊,患者自述:高血压病史6年,一直服用心痛定(5mg/次、2次/日)控制血压,患者现已退休在家,平日喜欢高盐、高脂饮食,近日睡眠不规律、烦躁易怒,不爱运动,无烟酒嗜好,日常生活能力正常半月来头痛、头晕、乏力、视力模糊,自行将心痛定次数增加为每日3次,仍不见好转。检查:血压150/95mmHg(服药后);无高血压家族史,诊断为高血压。服用本实施例2之口服液,一天两次,每次一袋,早晚饭后服用,10天为一疗程,使用两个疗程后,患者血压降至123/76mmHg,继续用药两个疗程加以巩固,患者血压正常,身体好转,停药后三个月,血压稳定,无反弹。
病例2:
钱某,女,56岁,济南市历下区人。2013年10月来我处就诊。患者自述:二十余年前发现高血压(170/100mmHg)未经任何治疗,八年前有阵发心悸、气短发作;无结核、肝炎病史,无长期咳嗽、咳痰史,吸烟40年,不饮酒。检查:患者血压为176/108mmHg,为高血压2级。服用本发明实施例5之胶囊,一天两次,每次两粒,早晚饭后服用,10天为一疗程,使用两个疗程后,患者血压降至133/79mmHg,继续用药两个疗程加以巩固,患者血压正常,身体好转,停药后三个月,血压稳定,无反弹。
病例3:
孙某,男,40岁,烟台莱阳人。患者2013年6月因间断头晕、头痛1年余来我处就诊。患者于1年多以前发现劳累或生气后常有头晕、头痛,头晕非旋转性,不伴恶心和呕吐,休息后则完全恢复正常,不影响日常工作和生活,因此未到医院看过,半年前单位体检时测血压l40/90mmHg,未服药,一直上班。发病以来无心悸、气短和心前区痛,进食、睡眠好,二便正常,体重无明显变化。检查:患者血压为165/101mmHg。诊断为高血压2级。服用本发明实施例5之胶囊,一天两次,每次两粒,早晚饭后服用,10天为一疗程,使用两个疗程后患者血压降至123/76mmHg,继续用药两个疗程加以巩固,患者血压正常,身体好转,停药后三个月,血压稳定,无反弹。
病例4:
李某,女,49岁,淄博临淄人。2013年4月就诊,患者自述:患高血压2年半,最高时血压为220/120mmHg,未曾规律用药,无其他病史,有头昏症状。2011年6月来我处治疗,检查:患者血压180/112mmHg,血脂血糖均在正常范围内。心电图显示左心室肥厚改变。诊断为高血压3级。服用本发明实施例6之颗粒剂,一天两次,每次两袋,早晚饭后服用,10天为一疗程,使用两个疗程后,测得血压值为150/98mmHg,头昏不适症状消失,继续用药两个疗程,患者血压值为110-120/60-70mmHg,血压降到正常值,两个月后检查血压无反弹。
病例5:
江某,男,52岁,青岛崂山人。2014年1月就诊,患者当时症状:眩晕、头痛、头昏,原因不明。患者血压为:低压110mmhg,高压180mmhg,病情持续3年,脉洪大,舌暗红,苔厚腻。临床诊断为:年老气血虚弱,脉失濡养,髓海空虚,淤血阻络,肝肾阴虚,肝阳上亢,由此造成血管垃圾(动脉垢)堆积过多,血管血流阻力大,不通则堵(阻),血流运行不畅,从中压迫小动脉平滑肌,造成小动脉平滑肌张力增大,小动脉平滑肌张力高于正常值,因而产生高血压,故临床诊断为高血压。服用本发明实施例6之片剂,一天两次,每次三片,早晚饭后服用10天为一疗程,使用两个疗程后,患者血压即降低为:低压78mmhg,高压136mmhg。后坚持服用两个疗程,血压在正常值保持平稳,未反弹。
最后应说明的是:以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (10)
1.一种治疗高血压的药物组合物,其特征在于:所述药物组合物的原料药由黄芩、白芷、徐长卿、荷叶、地龙、淫羊藿、麦冬、钩藤、葛根、杜仲、吴茱萸、夏枯草、菊花、天麻、夜交藤、桑寄生、益母草、香附、半夏、木通、芡实、沙棘、丝瓜藤、桑叶、牡丹皮、紫苏、银杏叶、白蒺藜、栀子、覆盆子、石斛、绞股蓝组成。
2.根据权利要求1所述的治疗高血压的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:夏枯草12-20份,黄芩10-16份,芡实3-8份,白芷5-12份,荷叶12-17份,徐长卿7-12份,益母草4-9份,麦冬15-20份,白蒺藜10-15份,菊花8-12份,天麻2-5份,淫羊藿3-7份,桑寄生11-14份,钩藤9-15份,沙棘3-6份,香附8-13份,木通3-5份,杜仲1-3份,丝瓜藤5-10份,吴茱萸5-10份,桑叶13-16份,地龙3-10份,牡丹皮8-13份,银杏叶3-5份,半夏1-3份,葛根5-10份,紫苏3-6份,夜交藤8-13份,栀子3-5份,覆盆子11-15份,石斛5-10份,绞股蓝4-8份。
3.根据权利要求1所述的治疗高血压的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:夏枯草12份,黄芩16份,芡实3份,白芷12份,荷叶12份,徐长卿10份,益母草9份,麦冬15份,白蒺藜15份,菊花8份,天麻5份,淫羊藿3份,桑寄生14份,钩藤9份,沙棘6份,香附8份,木通5份,杜仲1份,丝瓜藤10份,吴茱萸5份,桑叶16份,地龙10份,牡丹皮8份,银杏叶5份,半夏1份,葛根10份,紫苏6份,夜交藤8份,栀子3份,覆盆子15份,石斛5份,绞股蓝4份。
4.根据权利要求1所述的治疗高血压的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:夏枯草20份,黄芩10份,芡实8份,白芷5份,荷叶17份,徐长卿12份,益母草4份,麦冬20份,白蒺藜10份,菊花12份,天麻2份,淫羊藿7份,桑寄生11份,钩藤15份,沙棘3份,香附13份,木通3份,杜仲3份,丝瓜藤5份,吴茱萸10份,桑叶13份,地龙3份,牡丹皮13份,银杏叶3份,半夏3份,葛根5份,紫苏4份,夜交藤10份,栀子4份,覆盆子13份,石斛6份,绞股蓝5份。
5.根据权利要求1所述的治疗高血压的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:夏枯草13份,黄芩11份,芡实4份,白芷6份,荷叶13份,徐长卿7份,益母草5份,麦冬18份,白蒺藜11份,菊花9份,天麻4份,淫羊藿6份,桑寄生12份,钩藤13份,沙棘4份,香附9份,木通4份,杜仲2份,丝瓜藤6份,吴茱萸6份,桑叶14份,地龙5份,牡丹皮10份,银杏叶4份,半夏2份,葛根6份,紫苏5份,夜交藤12份,栀子3份,覆盆子12份,石斛9份,绞股蓝6份。
6.根据权利要求1所述的治疗高血压的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:夏枯草17份,黄芩15份,芡实7份,白芷11份,荷叶16份,徐长卿8份,益母草8份,麦冬16份,白蒺藜14份,菊花11份,天麻3份,淫羊藿5份,桑寄生13份,钩藤14份,沙棘5份,香附12份,木通3份,杜仲1份,丝瓜藤10份,吴茱萸9份,桑叶13份,地龙7份,牡丹皮11份,银杏叶3份,半夏1份,葛根10份,紫苏4份,夜交藤11份,栀子4份,覆盆子14份,石斛8份,绞股蓝7份。
7.根据权利要求1所述的治疗高血压的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:夏枯草15份,黄芩12份,芡实5份,白芷9份,荷叶15份,徐长卿9份,益母草7份,麦冬19份,白蒺藜13份,菊花10份,天麻4份,淫羊藿4份,桑寄生11份,钩藤11份,沙棘5份,香附10份,木通5份,杜仲3份,丝瓜藤8份,吴茱萸8份,桑叶14份,地龙9份,牡丹皮12份,银杏叶5份,半夏3份,葛根8份,紫苏6份,夜交藤9份,栀子5份,覆盆子12份,石斛7份,绞股蓝7份。
8.根据权利要求1所述的治疗高血压的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:夏枯草19份,黄芩14份,芡实6份,白芷7份,荷叶14份,徐长卿9份,益母草6份,麦冬17份,白蒺藜13份,菊花10份,天麻4份,淫羊藿4份,桑寄生11份,钩藤11份,沙棘5份,香附10份,木通5份,杜仲3份,丝瓜藤8份,吴茱萸8份,桑叶14份,地龙4份,牡丹皮9份,银杏叶5份,半夏3份,葛根8份,紫苏3份,夜交藤8份,栀子5份,覆盆子15份,石斛7份,绞股蓝8份。
9.根据权利要求3-8任一所述的治疗高血压的药物组合物,其特征在于:所述药物组合物按照下列方法进行制备:
(1)取权利要求3-8任一所述药物组合物中重量组分的各药材,加入8-12倍量的乙醇中浸泡1.5-2.5小时,加热提取2次,每次1.5-2小时,去上清液,合并提取液,120目滤过,再经截流分子量为8000-12000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.3-1.4的浸膏,加热浓缩至膏状,静置备用;
(2)将乙醇提取过的药渣放入10-12倍量水中,然后放入提取罐加热煮沸1.5-2小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;
(3)将步骤(2)中2次滤液合在一起,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2-3h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状;
(4)将步骤(1)浓缩得到的膏状物与步骤(3)得到的糊状物减压回收乙醇并浓缩至药液浓度为0.65-0.7g生药/mL,抽滤后,滤液的相对密度约为20℃时1.1-1.2;在3000r/min的转速下离心;在60℃-80℃喷雾干燥,得干浸膏;
(5)将步骤(4)制得的干浸膏粉碎,加入适量蔗糖、糊精混合,以乙醇为润湿剂,制粒,干燥,整粒,可制得颗粒剂;或者将步骤(4)制得的干浸膏干燥,粉碎,制成散剂;或者将步骤(4)制得的干浸膏粉碎,加入适量微粉硅胶、α-半乳糖混合,以乙醇为润湿剂,制粒,干燥,整粒,装胶囊,制得胶囊剂;或者将步骤(4)制得的干浸膏粉碎,加入适量蔗糖、糊精混合,以乙醇为润湿剂,制粒,干燥,整粒,压片,制得片剂;或者向上述步骤(4)得到的离心后的浓缩液中加入适量蔗糖、香精混合,灭菌,灌装,制得药液剂。
10.如权利要求1-9任一所述的治疗高血压的药物组合物在治疗高血压药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510218700.2A CN104815192A (zh) | 2015-04-30 | 2015-04-30 | 一种治疗高血压的药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510218700.2A CN104815192A (zh) | 2015-04-30 | 2015-04-30 | 一种治疗高血压的药物组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104815192A true CN104815192A (zh) | 2015-08-05 |
Family
ID=53725836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510218700.2A Pending CN104815192A (zh) | 2015-04-30 | 2015-04-30 | 一种治疗高血压的药物组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104815192A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105664048A (zh) * | 2016-03-04 | 2016-06-15 | 青岛市市立医院 | 一种抑制胃癌细胞增殖的药物组合物及其应用 |
CN105832934A (zh) * | 2016-06-12 | 2016-08-10 | 宋兴刚 | 一种治疗高血压病的中药 |
CN105902815A (zh) * | 2016-05-26 | 2016-08-31 | 李旭东 | 一种治疗治疗肾性高血压的中药汤剂 |
CN105902853A (zh) * | 2016-05-17 | 2016-08-31 | 商皓 | 一种治疗高血压的中药制剂 |
CN114796201A (zh) * | 2022-05-10 | 2022-07-29 | 南京鼓楼医院 | 佛手柑内酯作为制备治疗缺血性脑卒中药物的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130125952A (ko) * | 2012-05-10 | 2013-11-20 | 학교법인 선목학원 | 골무꽃 추출물 또는 이로부터 분리된 화합물을 함유하는 혈관 질환의 치료 또는 예방용 조성물 |
CN104352758A (zh) * | 2014-11-30 | 2015-02-18 | 侯德润 | 一种治疗高血压的药物及其制备方法 |
CN104435153A (zh) * | 2014-12-24 | 2015-03-25 | 刘保祥 | 一种治疗高血压的中药组合物及制法 |
-
2015
- 2015-04-30 CN CN201510218700.2A patent/CN104815192A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130125952A (ko) * | 2012-05-10 | 2013-11-20 | 학교법인 선목학원 | 골무꽃 추출물 또는 이로부터 분리된 화합물을 함유하는 혈관 질환의 치료 또는 예방용 조성물 |
CN104352758A (zh) * | 2014-11-30 | 2015-02-18 | 侯德润 | 一种治疗高血压的药物及其制备方法 |
CN104435153A (zh) * | 2014-12-24 | 2015-03-25 | 刘保祥 | 一种治疗高血压的中药组合物及制法 |
Non-Patent Citations (2)
Title |
---|
于虹: "《临床常用百药精解》", 31 January 2003 * |
姚卫海: "《实用膏方》", 31 January 2014 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105664048A (zh) * | 2016-03-04 | 2016-06-15 | 青岛市市立医院 | 一种抑制胃癌细胞增殖的药物组合物及其应用 |
CN105902853A (zh) * | 2016-05-17 | 2016-08-31 | 商皓 | 一种治疗高血压的中药制剂 |
CN105902815A (zh) * | 2016-05-26 | 2016-08-31 | 李旭东 | 一种治疗治疗肾性高血压的中药汤剂 |
CN105832934A (zh) * | 2016-06-12 | 2016-08-10 | 宋兴刚 | 一种治疗高血压病的中药 |
CN114796201A (zh) * | 2022-05-10 | 2022-07-29 | 南京鼓楼医院 | 佛手柑内酯作为制备治疗缺血性脑卒中药物的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN102058715B (zh) | 一种治疗慢性前列腺炎的中药制剂及其制备方法 | |
CN104815192A (zh) | 一种治疗高血压的药物组合物及其应用 | |
CN103705751B (zh) | 用于治疗风湿腰痛的中药组合物及其制备方法 | |
CN102178877B (zh) | 一种治疗阴囊湿疹的外用制剂及其制备方法 | |
CN103877247B (zh) | 用于治疗褥疮的药物及其制备方法 | |
CN103750024A (zh) | 用于治疗母猪尿闭症的饲料及其制备方法 | |
CN103432559A (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
CN106994141B (zh) | 一种治疗便秘的中药组合物及其制备方法 | |
CN103919899A (zh) | 一种药物组合物及其制备方法、制剂与应用 | |
CN105232987A (zh) | 一种促进神经外科术后康复的中药 | |
CN102430013A (zh) | 治疗白癜风的中药 | |
CN104940718A (zh) | 一种治疗慢性胆囊炎的药物组合物及其制备方法 | |
CN105169018A (zh) | 一种普外科治疗痔疮的中药组合物 | |
CN100431578C (zh) | 一种治疗前列腺增生的中药制剂 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN105435190A (zh) | 用于治疗寒热错杂型哮病的中药组合物及其制备方法 | |
CN104840864B (zh) | 一种治疗小儿脾虚型腹泻的中药制剂 | |
CN105106696A (zh) | 一种治疗慢性前列腺炎的中药组合物 | |
CN116459314B (zh) | 一种延缓衰老喷剂 | |
CN103690817B (zh) | 用于治疗母猪尿闭症的药物及其制备方法 | |
CN106729328A (zh) | 一种治疗癌症的中药组合物及其应用 | |
CN106620367A (zh) | 一种治疗膀胱结石的中药缓释胶囊及制备方法 | |
CN105267815A (zh) | 一种治疗小儿肺肾两虚型哮喘的喷雾剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150805 |